Giant dysgerminoma with pelvic metastases at the time of puberty: A case report and review of the literature
DOI:
https://doi.org/10.54502/msuceva.v3n2a2Palabras clave:
Diagnosis, ovarian dysgerminoma, neoplasm, surgical technique, treatmentResumen
This study aims to provide a comprehensive insight into the clinical presentation, diagnostic challenges and management strategies associated with a rare occurrence of giant dysgerminoma with pelvic metastases in an adolescent patient. We intend to add valuable information to the medical literature that may help to better understand and manage similar cases in the future, making this case report potentially valuable to clinicians and researchers in the fields of gynaecological oncology and paediatric oncology. Germ cells, the precursors of the ova in women and sperm in men, can give rise to germ cell tumours if their migration goes wrong during embryogenesis. These tumours, which can be malignant or benign, are generally rare. In particular, germ cell lesions in women are usually benign, whereas in men they are often malignant. These tumours can present as intra- or extragonadal masses due to the migratory nature of the germ cells. Dysgerminoma, a rare malignant germ cell tumour, is more common in men than testicular seminoma. In women, dysgerminomas account for 1-2% of malignant ovarian tumours and present as exotic lesions. They are usually relatively small, but giant lesions have been reported. They also exhibit rapid growth and a characteristic lobulated surface, retaining the ovarian shape. Extra-ovarian presentations are rare but may extend into the abdominal region. In men, seminomas may occur extra-testicularly, particularly in the mediastinum. Dysgerminomas respond well to radiotherapy and chemotherapy, with survival rates of over 90% at five years with timely and appropriate treatment worldwide
Descargas
Métricas
Citas
Tîrnovanu MC, Florea ID, Tănase A, Toma BF, Cojocaru E, Ungureanu C, et al. Uncommon Metastasis of Ovarian Dysgerminoma: A Case Report and Review of the Literature. Medicina (Buenos Aires) 2021;57:534. https://doi.org/10.3390/medicina57060534 DOI: https://doi.org/10.3390/medicina57060534
Frazier AL, F. Amatruda J. Pediatric Germ Cell Tumors. Oncology of Infancy and Childhood, Elsevier; 2009, p. 911–61. https://doi.org/10.1016/B978-1-4160-3431-5.00023-6 DOI: https://doi.org/10.1016/B978-1-4160-3431-5.00023-6
Mitranovici M-I, Chiorean DM, Mureșan MC, Buicu C-F, Moraru R, Moraru L, et al. Diagnosis and Management of Dysgerminomas with a Brief Summary of Primitive Germ Cell Tumors. Diagnostics 2022;12:3105. https://doi.org/10.3390/diagnostics12123105 DOI: https://doi.org/10.3390/diagnostics12123105
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51. https://doi.org/10.1093/neuonc/noab106 DOI: https://doi.org/10.1093/neuonc/noab106
Sas I, Şerban DM, Tomescu L-C, Nicolae N. Ovarian dysgerminoma in pregnancy. Medicine 2021;100:e25364. https://doi.org/10.1097/MD.0000000000025364 DOI: https://doi.org/10.1097/MD.0000000000025364
Kudoh K, Kikuchi Y, Kita T, Tode T, Takano M, Hirata J, et al. Preoperative Determination of Several Serum Tumor Markers in Patients with Primary Epithelial Ovarian Carcinoma. Gynecol Obstet Invest 1999;47:52–7. https://doi.org/10.1159/000010062 DOI: https://doi.org/10.1159/000010062
Khedr OS, Wahed ME, Al-Attar A-SR, Abdel-Rehim EA. The classification of the bladder cancer based on Vision Transformers (ViT). Sci Rep 2023;13:20639. https://doi.org/10.1038/s41598-023-47992-y DOI: https://doi.org/10.1038/s41598-023-47992-y
Zhao S, Sun F, Bao L, Chu C, Li H, Yin Q, et al. Pure dysgerminoma of the ovary: CT and MRI features with pathological correlation in 13 tumors. J Ovarian Res 2020;13:71. https://doi.org/10.1186/s13048-020-00674-z DOI: https://doi.org/10.1186/s13048-020-00674-z
Krenthel O, O E, C M, D A, RL DW, H K. Ovarian Dysgerminoma – Challenging Presurgical Diagnosis and Mini-Mally Invasive Treatment. Arch Clin Med Case Rep 2023;07. https://doi.org/10.26502/acmcr.96550573 DOI: https://doi.org/10.26502/acmcr.96550573
Villarreal Mejía J. Disgerminoma: actualización del tema y presentación de cinco casos. Rev Colomb Obstet Ginecol 1963;14:277–89. https://doi.org/10.18597/rcog.2340 DOI: https://doi.org/10.18597/rcog.2340
Socorro Castro C, Chávez Valdivia M, Martínez Navarro J. Disgerminoma puro de ovario en adolescente: presentación de un caso y revisión de la literatura. Revista Finlay 2018;8:321–6. http://scielo.sld.cu/pdf/rf/v8n4/rf10408.pdf
Mann JR, Raafat F, Robinson K, Imeson J, Gornall P, Sokal M, et al. The United Kingdom children’s cancer study group’s second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. Journal of Clinical Oncology 2000;18:3809–18. https://doi.org/10.1200/JCO.2000.18.22.3809 DOI: https://doi.org/10.1200/JCO.2000.18.22.3809
Verdecia Cañizares C, Portugués Díaz A. Tumores germinales malignos de ovario en niñas y adolescentes. Rev Cubana Pediatr 2006;78:1–5. http://scielo.sld.cu/pdf/ped/v78n4/ped05406.pdf
Höhn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn L-C. 2020 WHO Classification of Female Genital Tumors. Geburtshilfe Frauenheilkd 2021;81:1145–53. https://doi.org/10.1055/a-1545-4279 DOI: https://doi.org/10.1055/a-1545-4279
Kaur B. Pathology of malignant ovarian germ cell tumours. Diagn Histopathol 2020; 26:289–97. https://doi.org/10.1016/j.mpdhp.2020.03.006 DOI: https://doi.org/10.1016/j.mpdhp.2020.03.006
Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, et al. Incidence and Survival Rates for Female Malignant Germ Cell Tumors. Obstetrics & Gynecology 2006; 107:1075–85. https://doi.org/10.1097/01.AOG.0000216004.22588.ce DOI: https://doi.org/10.1097/01.AOG.0000216004.22588.ce
Gordon A, Lipton D, Woodruff JD. Dysgerminoma: a review of 158 cases from the Emil Novak Ovarian Tumor Registry. Obstetrics and Gynecology 1981; 58:497–504.
Lim D, Oliva E. Gynecological neoplasms associated with paraneoplastic hypercalcemia. Semin Diagn Pathol 2019; 36:246–59. https://doi.org/10.1053/j.semdp.2019.01.003 DOI: https://doi.org/10.1053/j.semdp.2019.01.003
Mailliez A, Pigny P, Bogart E, Keller L, D’Orazio E, Vanseymortier M, et al. Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients. Int J Cancer 2022; 150:1850–60. https://doi.org/10.1002/ijc.33933 DOI: https://doi.org/10.1002/ijc.33933
Oliveira M de MS, Salgado C de M, Viana LR, Gomes-Marcondes MCC. Pregnancy and Cancer: Cellular Biology and Mechanisms Affecting the Placenta. Cancers (Basel) 2021;13. https://doi.org/10.3390/cancers13071667 DOI: https://doi.org/10.3390/cancers13071667
Adhikari S, Joti S, Chhetri PK. Paediatric Ovarian Dysgerminoma: A Case Report. Journal of Nepal Medical Association 2022;60:985–8. https://doi.org/10.31729/jnma.7894 DOI: https://doi.org/10.31729/jnma.7894
Triarico S, Capozza MA, Mastrangelo S, Attinà G, Maurizi P, Ruggiero A. Gynecological cancer among adolescents and young adults (AYA). Ann Transl Med 2020; 8:397–397. https://doi.org/10.21037/atm.2020.02.41 DOI: https://doi.org/10.21037/atm.2020.02.41
Vázquez-Manjarrez SE, Rico-Rodriguez OC, Guzman-Martinez N, Espinoza-Cruz V, Lara-Nuñez D. Imaging and diagnostic approach of the adnexal mass: what the oncologist should know. Chin Clin Oncol 2020; 9:69–69. https://doi.org/10.21037/cco-20-37. DOI: https://doi.org/10.21037/cco-20-37
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Medina Torres & Restrepo Becerra
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Magna Scientia UCEVA proporciona un acceso abierto, libre y gratuito a su contenido, basado en el principio de que ofrecer al público un acceso libre a las investigaciones, ayuda a un mayor intercambio global del conocimiento. Lo cual, implica que los usuarios pueden leer, descargar, almacenar, imprimir, buscar, indexar y realizar enlaces a los textos completos de esta revista. Se permite distribuir los diversos artículos en las versiones post-print y oficial, sin previo permiso del autor o editor, considerando que el fin de este, no implica fines comerciales, ni la generación de obras derivadas; Solo se solicita la mención de la fuente así como la autoría. El titular del copyright será el o los autores que publiquen en Magna Scientia UCEVA.
Magna Scientia UCEVA está distribuida bajo los términos de la licencia https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es